Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Jianqiu Wu"'
Autor:
Hui Li, Peng Liu, Yao Liu, Liang Huang, Yuhua Li, QingQing Cai, Huilai Zhang, Jian-Qing Mi, Zhi Wang, Ting Niu, Dehui Zou, Wenyan Yu, Heng Mei, Jianqiu Wu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Relapsed/refractory (R/R) central nervous system lymphomas (CNSLs) are associated with a poor prognosis. Relmacabtagene autoleucel (relma-cel), expressing the same chimeric antigen receptor (CAR) as lisocabtagene maraleucel, with an optimi
Externí odkaz:
https://doaj.org/article/24bef32138f34ab0902b75cfac321656
Publikováno v:
BMC Bioinformatics, Vol 24, Iss 1, Pp 1-18 (2023)
Abstract Accurately predicting the binding affinity between proteins and ligands is crucial for drug discovery. Recent advances in graph neural networks (GNNs) have made significant progress in learning representations of protein-ligand complexes to
Externí odkaz:
https://doaj.org/article/7c6c561bfd9d48ca8a1f7f0cc4d64f35
Publikováno v:
HemaSphere, Vol 7, p e8841234 (2023)
Externí odkaz:
https://doaj.org/article/dd868cdba90b4663a343daf189cef3a6
Autor:
Yan Lv, Yuxin Du, Kening Li, Xiao Ma, Juan Wang, Tongde Du, Yuxin Ma, Yue Teng, Weiyan Tang, Rong Ma, Jianqiu Wu, Jianzhong Wu, Jifeng Feng
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background Aggressive B-cell non-Hodgkin’s lymphoma (B-NHL) patients often develop drug resistance and tumor recurrence after conventional immunochemotherapy, for which new treatments are needed. Methods We investigated the antitumor effec
Externí odkaz:
https://doaj.org/article/87ad612d2b694c98b90635a46cd78e34
Publikováno v:
Mathematics, Vol 11, Iss 16, p 3600 (2023)
During the operation period of tunnels in urban deep aquifer zones, the geological environment around the tunnel is complex and the surrounding strata are rich in groundwater, which often poses a risk of structure cracking and groundwater leakage, se
Externí odkaz:
https://doaj.org/article/d8e82791a2d24618a508e996c8b66364
Autor:
Zhiya Wu, Yue Teng, Jianqiu Wu, Honglu Zhang, Weiwei Peng, Cheng Meng, Weiyan Tang, Jifeng Feng
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) has been rarely reported because of its low incidence. The optimal treatment plan for patients with relapsed/refractory PB-DLBCL remains controversial. In this study, we present a case of a 57-yea
Externí odkaz:
https://doaj.org/article/a08abce9ee0b4e54883fd720ec435f3d
Autor:
Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Pian Zhang, Su Yang, Zisong Zhou, Hongxia Zheng, Yuqin Song, Jun Zhu
Publikováno v:
Cancer Medicine, Vol 10, Iss 3, Pp 999-1011 (2021)
Abstract Background Despite numerous chimeric antigen receptor T‐cell (CAR‐T) trials conducted in China, no CAR‐T has been registered in the country. Furthermore, China law and regulations restrict the export of patient material for CAR‐T man
Externí odkaz:
https://doaj.org/article/13ad08ffbb1e4d2f8499a2bb859c0626
Autor:
Yuankai Shi, Jianqiu Wu, Zhen Wang, Liling Zhang, Zhao Wang, Mingzhi Zhang, Hong Cen, Zhigang Peng, Yufu Li, Lei Fan, Ye Guo, Liping Ma, Jie Cui, Yuhuan Gao, Haiyan Yang, Hongyu Zhang, Lin Wang, Weihua Zhang, Huilai Zhang, Liping Xie, Ming Jiang, Hui Zhou, Yuerong Shuang, Hang Su, Xiaoyan Ke, Chuan Jin, Xin Du, Li Liu, Yaming Xi, Zheng Ge, Ru Feng, Yang Zhang, Shengyu Zhou, Fan Xie, Qian Wang
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-13 (2021)
Abstract Background Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety of geptanolimab (GB226
Externí odkaz:
https://doaj.org/article/7e43576f16064c5f8c7daf2c4245a7da
Autor:
Yuankai Shi, Bo Jia, Wei Xu, Wenyu Li, Ting Liu, Peng Liu, Weili Zhao, Huilai Zhang, Xiuhua Sun, Haiyan Yang, Xi Zhang, Jie Jin, Zhengming Jin, Zhiming Li, Lugui Qiu, Mei Dong, Xiaobing Huang, Yi Luo, Xiaodong Wang, Xin Wang, Jianqiu Wu, Jingyan Xu, Pingyong Yi, Jianfeng Zhou, Hongming He, Lin Liu, Jianzhen Shen, Xiaoqiong Tang, Jinghua Wang, Jianmin Yang, Qingshu Zeng, Zhihui Zhang, Zhen Cai, Xiequn Chen, Kaiyang Ding, Ming Hou, Huiqiang Huang, Xiaoling Li, Rong Liang, Qifa Liu, Yuqin Song, Hang Su, Yuhuan Gao, Lihong Liu, Jianmin Luo, Liping Su, Zimin Sun, Huo Tan, Huaqing Wang, Jingwen Wang, Shuye Wang, Hongyu Zhang, Xiaohong Zhang, Daobin Zhou, Ou Bai, Gang Wu, Liling Zhang, Yizhuo Zhang
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2017)
Abstract The efficacy and safety of chidamide, a new subtype-selective histone deacetylase (HDAC) inhibitor, have been demonstrated in a pivotal phase II clinical trial, and chidamide has been approved by the China Food and Drug Administration (CFDA)
Externí odkaz:
https://doaj.org/article/fb0461c9c99841929ebde75677646c99
Autor:
Zhitao Ying, Haiyan Yang, Ye Guo, Wenyu Li, Dehui Zou, Daobin Zhou, Zhao Wang, Mingzhi Zhang, Jianqiu Wu, Hui Liu, Chris Wang, Laura Ma, Su Yang, Zisong Zhou, Yun Qin, Yuqin Song, Jun Zhu
Publikováno v:
Cytotherapy. 25:521-529